DSM-5精神病学诊断和阿片类药物使用障碍

N. S. Miller, Thersilla Oberbarnscheidt
{"title":"DSM-5精神病学诊断和阿片类药物使用障碍","authors":"N. S. Miller, Thersilla Oberbarnscheidt","doi":"10.4172/2155-6105.1000310","DOIUrl":null,"url":null,"abstract":"The treatment of pain with opioid medications is a nowadays frequently discussed and concerning topic. Opioid medications have been prescribed since ancient years even though they are known to cause severe adverse reactions and co-morbid reactions. Depression and anxiety are the most common co-morbid psychiatric conditions observed in patients receiving opioid treatment. In the majority of cases, the provider for the pain medicine and the provider for the mood disturbance are not the same, which complicates diagnosis and treatment. The presenting symptoms of depression and anxiety are frequently not contributed to the opioid medication. Opioids cause anxiety through development of dependence and withdrawal as evidenced by the need to dose opioids frequently throughout a 24 h period. To treat opioid induced anxiety and depression associated with chronic use of opioid medications, physicians frequently concomitantly prescribe anxiolytics like benzodiazepines. Benzodiazepines significantly exacerbate both substance induced depression and anxiety. The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) clearly requires the exclusion of the influence of a substance in order to diagnose major depressive disorder or generalized anxiety disorder but those are frequently given even though the patient is receiving treatment with opioid medications. Ultimately the correct diagnosis is crucial for the right treatment. This article is a review of literature discussing the correlation of opioid treatment and co-morbid psychiatric diagnoses including the differentiation as well as diagnostic criteria.","PeriodicalId":14828,"journal":{"name":"Journal of Addiction Research and Therapy","volume":"47 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2017-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"DSM-5 Psychiatric Diagnoses and Opioid Use Disorder\",\"authors\":\"N. S. Miller, Thersilla Oberbarnscheidt\",\"doi\":\"10.4172/2155-6105.1000310\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The treatment of pain with opioid medications is a nowadays frequently discussed and concerning topic. Opioid medications have been prescribed since ancient years even though they are known to cause severe adverse reactions and co-morbid reactions. Depression and anxiety are the most common co-morbid psychiatric conditions observed in patients receiving opioid treatment. In the majority of cases, the provider for the pain medicine and the provider for the mood disturbance are not the same, which complicates diagnosis and treatment. The presenting symptoms of depression and anxiety are frequently not contributed to the opioid medication. Opioids cause anxiety through development of dependence and withdrawal as evidenced by the need to dose opioids frequently throughout a 24 h period. To treat opioid induced anxiety and depression associated with chronic use of opioid medications, physicians frequently concomitantly prescribe anxiolytics like benzodiazepines. Benzodiazepines significantly exacerbate both substance induced depression and anxiety. The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) clearly requires the exclusion of the influence of a substance in order to diagnose major depressive disorder or generalized anxiety disorder but those are frequently given even though the patient is receiving treatment with opioid medications. Ultimately the correct diagnosis is crucial for the right treatment. This article is a review of literature discussing the correlation of opioid treatment and co-morbid psychiatric diagnoses including the differentiation as well as diagnostic criteria.\",\"PeriodicalId\":14828,\"journal\":{\"name\":\"Journal of Addiction Research and Therapy\",\"volume\":\"47 1\",\"pages\":\"1-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-03-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Addiction Research and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2155-6105.1000310\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Addiction Research and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-6105.1000310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

用阿片类药物治疗疼痛是当今人们经常讨论和关注的话题。阿片类药物自古以来就被开处方,尽管已知它们会引起严重的不良反应和共病反应。抑郁和焦虑是在接受阿片类药物治疗的患者中观察到的最常见的共病精神疾病。在大多数情况下,止痛药的提供者和情绪障碍的提供者是不同的,这使诊断和治疗复杂化。出现的抑郁和焦虑症状通常不是阿片类药物引起的。阿片类药物通过依赖和戒断的发展引起焦虑,需要在24小时内频繁服用阿片类药物。为了治疗与长期使用阿片类药物相关的阿片类药物引起的焦虑和抑郁,医生经常同时开出苯二氮卓类抗焦虑药。苯二氮卓类药物显著加重物质诱导的抑郁和焦虑。《精神疾病诊断和统计手册》第5版(DSM-5)明确要求排除某种物质的影响,以便诊断严重抑郁症或广泛性焦虑症,但即使患者正在接受阿片类药物治疗,也经常给予这些影响。最终,正确的诊断对正确的治疗至关重要。本文综述了阿片类药物治疗与精神科共病诊断的相关文献,包括阿片类药物的鉴别和诊断标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
DSM-5 Psychiatric Diagnoses and Opioid Use Disorder
The treatment of pain with opioid medications is a nowadays frequently discussed and concerning topic. Opioid medications have been prescribed since ancient years even though they are known to cause severe adverse reactions and co-morbid reactions. Depression and anxiety are the most common co-morbid psychiatric conditions observed in patients receiving opioid treatment. In the majority of cases, the provider for the pain medicine and the provider for the mood disturbance are not the same, which complicates diagnosis and treatment. The presenting symptoms of depression and anxiety are frequently not contributed to the opioid medication. Opioids cause anxiety through development of dependence and withdrawal as evidenced by the need to dose opioids frequently throughout a 24 h period. To treat opioid induced anxiety and depression associated with chronic use of opioid medications, physicians frequently concomitantly prescribe anxiolytics like benzodiazepines. Benzodiazepines significantly exacerbate both substance induced depression and anxiety. The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) clearly requires the exclusion of the influence of a substance in order to diagnose major depressive disorder or generalized anxiety disorder but those are frequently given even though the patient is receiving treatment with opioid medications. Ultimately the correct diagnosis is crucial for the right treatment. This article is a review of literature discussing the correlation of opioid treatment and co-morbid psychiatric diagnoses including the differentiation as well as diagnostic criteria.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信